HUANG Hefei
1. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.2. Three Gorges Center for Food and Drug Control, Yichang 443002QIANG Weijie
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, ChinaYANG Qing
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, ChinaLI Yujie
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, ChinaWENG Xiaogang
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, ChinaWENG Xiaogang
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, ChinaLI Qi
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, ChinaCAI Weiyan
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, ChinaCHEN Tao
Medical Science College, China Three Gorges University, Yichang 443002ZHU Xiaoxin
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, ChinaCHEN Ying
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China(1. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.2. Medical Science College, China Three Gorges University, Yichang 443002. 3. Three Gorges Center for Food and Drug Control, Yichang 443002)
National Natural Science Foundation of China(No. 81403171), Major New Drug Creation Foundation of China(No. 2017ZX09101002-002-008)and Autonomous Program of China Academy of Chinese Medical Sciences (No. QZPT001)
Objective To explore the biological indicators of diagnosis and treatment of irritable bowel syndrome (IBS), and to explore the mechanism of action of a Chinese medicine Wuji Pill (WJW) on irritable bowel syndrome (IBS). Methods (1) Postinflammatory irritable bowel syndrome (PI-IBS) rat model was established by acetic acid plus restraint stress method . (2) The colonic motor ability of rats was evaluated by colon motility index (MI), the number of fecal particles discharged within 2 h, and the time of glass pellet discharge. (3) The formation of PI-IBS model rats and the therapeutic effect of WJW were observed. (4) The levels of calcitonin gene-related peptide (CGRP), motilin (MTL), neuropeptide Y (NPY), substance P (SP), somatostatin (SS), vasoactive intestinal peptide (VIP), and cholecystokinin (CCK) in the brain and colon tissues of PI-IBS rats were measured by ELISA. Results (1) The rat PI-IBS model was successfully established. Compared with the normal group, the body weight of the model rats was decreased, the food intake decreased, the amount of feces increased, loose stools and amorphous soft stools appeared, voluntary movements decreased, colon motility index (MI) significantly increased ( P < 0.05), the number of fecal particles discharged significantly increased ( P < 0.05), and the glass pellet discharge time was significantly shortened ( P < 0.05). (2) WJW treatment for 7 days significantly improved a variety of symptoms. Compared with the normal control, the levels of CGRP, SS and VIP in the brain tissue of PI-IBS rats were significantly increased ( P < 0.05), and the NPY concentration was significantly decreased ( P < 0.05). However, the treatment with WJW significantly reduced CGRP, SS and VIP levels ( P < 0.05), and significantly increased the NPY concentration level ( P < 0.05). (3) Compared with the normal control group, the levels of CCK, NPY, MTL, SS and VIP in colonic tissues of PI-IBS rats were significantly decreased ( P < 0.05), while WJW significantly increased the CCK and VIP levels. Conclusions WJW can be used to treat IBS by regulating the levels of various brain-gut peptides in the brain and colon tissues of IBS rats. These anomalous and adjustable brain-gut peptides may become a potential biomarker for the diagnosis and treatment of IBS.
